Short answer
Bio-rad Laboratories Inc (BIO) filed its fiscal 2013 10-K annual report with the SEC on Mar 18, 2014.
- Top risk flagged: DOJ and SEC FCPA investigations: $35.0 million estimated loss contingency, including $5.0 million accrued interest
Bio-rad Laboratories Inc FY2013 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Dual-segment model: Life Science research tools and Clinical Diagnostics systems, reagents, software, and controls
- Global mix: Clinical Diagnostics 66% of sales, Life Science 33%, with 68% of sales outside the United States
- Product breadth emphasized: more than 5,000 life science products and over 3,000 diagnostic products covering 300-plus tests
- R&D investment reached $211.0 million, up from $209.2 million in 2012 and $177.6 million in 2011
- Approximately 7,750 employees and 1,000 global sales and service personnel at December 31, 2013
Management Discussion & Analysis
- Revenue $2.13B, up from $2.07B, currency-neutral growth 3.9%
- Gross margin 55.3% vs 55.8%; net margin 3.6% vs 8.0%
- Clinical Diagnostics best segment, $1.41B sales; Life Science $710.0M, both up 3.1%
- Operating cash flow $175.5M; capex $113.0M; $300.0M debt redemption
- Outlook risks: government austerity, slower developed-market growth, currency volatility, FCPA accrual $35.0M
Risk Factors
- DOJ and SEC FCPA investigations: $35.0 million estimated loss contingency, including $5.0 million accrued interest
- European sovereign exposure: $66.0 million receivables in Spain, Italy, Greece and Portugal at December 31, 2013
- ERP implementation vulnerability: Clinical Diagnostics issues disrupted invoicing and increased accounts receivable in 2013
- Competitive pressure: Larger, less leveraged rivals can fund research, manufacturing and marketing more aggressively
- Ownership concentration: Schwartz family held 94% of Class B shares, enabling majority director elections at February 14, 2014
Generated from the filing text; verify against the original. How to read a 10-K
Other Bio-rad Laboratories Inc annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.